Paper3260908
Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
Ward BA and 4 others. J Immunol, 1988. Cited by 28 papers, by iCite.
Cite this record
ConductScience Library. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. Papers, record 3260908. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3260908
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cell Communication | Major topic |
| Immunization, Passive | Major topic |
| Sarcoma, Experimental | Major topic |
| T-Lymphocytes | Major topic |
| Animals | |
| Antigens, Differentiation, T-Lymphocyte | |
| Antigens, Ly | |
| Cell Line | |
| Clone Cells | |
| Female | |
| Histocompatibility Antigens Class II | |
| Immunity, Cellular | |
| Kinetics | |
| Lung Neoplasms | |
| Mice | |
| Mice, Inbred C57BL | |
| Neoplasm Metastasis | |
| Phenotype |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA-49231 | NCI NIH HHS | United States | R01CA049231 | PubMed and NIH |
Source NIH RePORTER
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 28 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 25545618 | Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL-10. | Eur J Immunol | 2015 | https://conductscience.org/library/papers/25545618 | PubMed |
| 19667089 | In vivo sensitized and in vitro activated B cells mediate tumor regression in cancer adoptive immunotherapy. | J Immunol | 2009 | https://conductscience.org/library/papers/19667089 | PubMed |
| 2574630 | Cancer patients' lymphocytes contain CD3+ CD4+ cells that proliferate in response to autologous tumor cells in the presence of exogenous low-dose interleukin-2 and autologous accessory cells. | Cancer Immunol Immunother | 1989 | https://conductscience.org/library/papers/2574630 | PubMed |
| 2302723 | Emergence of a dominant cytotoxic T lymphocyte antitumor effector from tumor-infiltrating cells in the anterior chamber of the eye. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2302723 | PubMed |
| 2126983 | Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes. | Cancer Immunol Immunother | 1990 | https://conductscience.org/library/papers/2126983 | PubMed |
| 1760813 | Tumour rejection after adoptive transfer of line-10-immune spleen cells is mediated by two T cell subpopulations. | Cancer Immunol Immunother | 1991 | https://conductscience.org/library/papers/1760813 | PubMed |
| 1532376 | The targeting of T-helper cells and tumourcidal macrophages to a B-cell lymphoma using a PPD-monoclonal antibody heteroconjugate. | Immunology | 1992 | https://conductscience.org/library/papers/1532376 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3260908
GET https://conductscience.org/api/papers/v1/3260908/authors